Brought to you by 
Depomed, Santarus ink new agreement for Glumetza
06 Nov 2015
Executive Summary
In a deal that replaces a mid-2008 promotion agreement, Depomed Inc. has now licensed Santarus Inc. US regulatory, commercial, and manufacturing rights to Glumetza (metformin) extended-release tablets for adults with Type II diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com